Klaria Pharma announces approval by the United Stated Patent and Trademark Office of a new patent application covering Naloxone Alginate Film.
With this approval of a new patent, Naloxone Alginate Film will enjoy patent-protected market exclusivity in the United States until 2038. The approval marks the second time the United States Patent Office (USPTO) has approved a compound/Alginate Film combination patent that protects an individual compound formulated in Klaria’s proprietary Alginate Film. Thus, the approval of the Naloxone Alginate Film combination patent validates Klaria’s patent strategy in the United States, the world’s most valuable market for pharmaceuticals.Jesper Wiklund, CEO of Klaria said “This approval gives us